MoonLake Immunotherapeutics
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
MLTX$12.56-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
The information required by this Item 14 is incorporated herein by reference to information in the 2025 Proxy Statement, including under the heading “Ratification of Independent Auditor Selection”.
s
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.